BRPI0813355A2 - Compostos de quinazolinona e métodos de uso dos mesmos - Google Patents

Compostos de quinazolinona e métodos de uso dos mesmos

Info

Publication number
BRPI0813355A2
BRPI0813355A2 BRPI0813355-7A2A BRPI0813355A BRPI0813355A2 BR PI0813355 A2 BRPI0813355 A2 BR PI0813355A2 BR PI0813355 A BRPI0813355 A BR PI0813355A BR PI0813355 A2 BRPI0813355 A2 BR PI0813355A2
Authority
BR
Brazil
Prior art keywords
methods
quinazolinone compounds
quinazolinone
compounds
Prior art date
Application number
BRPI0813355-7A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Jifeng Liu
Syed M Ali
Mark A Ashwell
Ping Ye
Yousheng Guan
Shi-Chung Ng
Rocio Palma
Dan Yohannes
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of BRPI0813355A2 publication Critical patent/BRPI0813355A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0813355-7A2A 2007-06-22 2008-06-19 Compostos de quinazolinona e métodos de uso dos mesmos BRPI0813355A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94583807P 2007-06-22 2007-06-22
PCT/US2008/067571 WO2009002808A2 (en) 2007-06-22 2008-06-19 Quinazolinone compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0813355A2 true BRPI0813355A2 (pt) 2014-12-30

Family

ID=39846620

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813355-7A2A BRPI0813355A2 (pt) 2007-06-22 2008-06-19 Compostos de quinazolinona e métodos de uso dos mesmos

Country Status (13)

Country Link
US (1) US8232285B2 (https=)
EP (1) EP2173724B1 (https=)
JP (1) JP2010530885A (https=)
KR (1) KR20100024494A (https=)
CN (1) CN101801937A (https=)
AU (1) AU2008268613A1 (https=)
BR (1) BRPI0813355A2 (https=)
CA (1) CA2704282A1 (https=)
IL (1) IL202740A0 (https=)
MX (1) MX2009013815A (https=)
TW (1) TW200918069A (https=)
WO (1) WO2009002808A2 (https=)
ZA (1) ZA201000183B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011242988B2 (en) * 2010-04-19 2013-02-07 Sri International Compositions and method for the treatment of multiple myeloma
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
US20150132575A1 (en) * 2013-11-14 2015-05-14 Honeywell International Inc. Luminescent fibers, articles including the same, and methods of forming the same
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3790878A1 (en) * 2018-05-11 2021-03-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Quinoline compounds and their preparation and use as antimalarial agents
CN113354590A (zh) * 2020-03-05 2021-09-07 宁波康柏睿格医药科技有限公司 拮抗nod1/2受体信号通路的喹唑啉酮类化合物

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG16042A3 (bg) 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
AU543928B2 (en) 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5187167A (en) 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
GB8707053D0 (en) 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
CZ280738B6 (cs) 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8827820D0 (en) 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5380746A (en) 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
CA2015996C (en) 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
IL98167A0 (en) 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
US5292747A (en) 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
US5591842A (en) 1991-11-29 1997-01-07 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
RU2104279C1 (ru) 1992-03-12 1998-02-10 Смитклайн Бичам Плс Конденсированное индольное производное или его фармацевтически приемлемая соль, фармацевтическая композиция, проявляющая активность антагониста 5-нт*004-рецептора
WO1993018765A1 (en) 1992-03-20 1993-09-30 The Wellcome Foundation Limited Indole derivatives with antiviral activity
US5721230A (en) 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
ES2236702T3 (es) 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
WO1995030682A1 (en) 1994-05-09 1995-11-16 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyprolocarbazole derivative
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
IL112125A (en) 1994-12-22 1998-02-08 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions
US5559228A (en) 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
EP0888339A4 (en) 1996-03-20 2001-02-28 Lilly Co Eli SYNTHESIS OF INDOLYLMALEINIMIDES
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91698A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
YU9499A (sh) 1996-08-23 2000-03-21 Eli Lilly And Company Sinteza bisindolilmalimida
SE9603283D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
AU4920397A (en) 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
US5859261A (en) 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
US6184377B1 (en) 1997-12-15 2001-02-06 Sepracor Inc. Compositions containing N-amino- and N-hydroxy-quinazolinones and methods for preparing libraries thereof
CA2338866A1 (en) 1998-07-30 2000-02-10 Japan Tobacco Inc. Disubstituted maleimide compound and pharmaceutical use thereof
AU2327700A (en) 1999-02-09 2000-08-29 Rei Asakai Pyrrole derivatives and cell death inhibitors
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ATE327224T1 (de) 1999-10-27 2006-06-15 Cytokinetics Inc Chinazolinone benutzende verfahren und zusammenstellungen
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
WO2001044247A2 (en) 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
ES2220585T3 (es) 1999-12-16 2004-12-16 Eli Lilly And Company Agentes y procedimiento para el tratamiento de enfermedades proliferativas.
US20030087949A1 (en) 2000-03-30 2003-05-08 Mikiko Sodeoka Indolylpyrrole derivatives and cell death inhibitors
MXPA02011079A (es) 2000-05-11 2004-08-19 Consejo Superior Investigacion Inhibidores heterociclicos de quinasa de sintasa de glucogeno gsk3.
EP1355921A2 (en) 2000-06-29 2003-10-29 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
US7074824B2 (en) 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6962944B2 (en) 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2002346471A1 (en) 2001-11-20 2003-06-10 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
WO2003066808A2 (en) 2002-01-23 2003-08-14 Texas Tech University Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells
WO2003070701A2 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses of quinazolinones
DK1483265T3 (da) 2002-03-05 2007-03-19 Lilly Co Eli Purinderivater som kinaseinhibitorer
US7214800B2 (en) 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004039774A2 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003256805A1 (en) 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
EP1620573A4 (en) 2003-04-15 2006-12-20 Avalon Pharmaceuticals DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
MXPA05012377A (es) 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
MXPA05013181A (es) 2003-06-06 2006-06-23 Genentech Inc Metodos y composiciones para modular hgf/met.
DE602004024536D1 (de) 2003-07-07 2010-01-21 Van Andel Res Inst Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
JP2008517064A (ja) 2004-10-19 2008-05-22 アークル インコーポレイテッド Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
ATE486872T1 (de) 2005-02-09 2010-11-15 Arqule Inc Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
KR20130114763A (ko) 2005-03-31 2013-10-18 더 제너럴 하스피탈 코포레이션 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
EP2013218A2 (en) 2006-04-17 2009-01-14 Arqule, Inc. Raf inhibitors and their uses

Also Published As

Publication number Publication date
EP2173724B1 (en) 2012-12-05
WO2009002808A3 (en) 2009-07-23
WO2009002808A2 (en) 2008-12-31
CN101801937A (zh) 2010-08-11
KR20100024494A (ko) 2010-03-05
ZA201000183B (en) 2011-03-30
US20090130097A1 (en) 2009-05-21
AU2008268613A1 (en) 2008-12-31
IL202740A0 (en) 2010-06-30
US8232285B2 (en) 2012-07-31
TW200918069A (en) 2009-05-01
MX2009013815A (es) 2010-03-01
JP2010530885A (ja) 2010-09-16
CA2704282A1 (en) 2008-12-31
EP2173724A2 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
BRPI0813355A2 (pt) Compostos de quinazolinona e métodos de uso dos mesmos
BRPI0815811A2 (pt) Derivados de indol substituído e métodos de uso dos mesmos
BRPI0808013A2 (pt) Compostos de quinoxalina e uso dos mesmos
BRPI0820457A2 (pt) Fluidos de ruptura e métodos de uso dos mesmos
BR112012003661A2 (pt) "compostos de biarila e métodos de uso dos mesmos."
BRPI0915231A2 (pt) compostos inibidores de quinase e métodos de uso
BRPI0807495A2 (pt) Adjuvantes e métodos de emrpego dos mesmos
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
BRPI0812909A2 (pt) Derivados de guanina policíclica e métodos de uso dos mesmos.
BRPI0821499A2 (pt) Artigos de filtração de fluído e métodos de preparo e uso dos mesmos
BRPI0909077A2 (pt) Artigos multicamadas e métodos de preparo e uso dos mesmos
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
CR10743A (es) Derivados de azaadamantano y metodos de uso de los mismos
BRPI0907236A2 (pt) inibidores de proteína quinase e uso dos mesmos
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BRPI0915717A2 (pt) ferramenta de avaliação de cascalho e métodos de uso
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0821110A2 (pt) Anticorpo anti nr-10 e uso do mesmo
PT2424896E (pt) Anticorpos anti-ceacam1 e métodos de utilização dos mesmos
BRPI1015315A2 (pt) composto heterocíclico fundido e uso dos mesmos
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.